U.S. markets closed
  • S&P 500

    3,821.35
    -20.59 (-0.54%)
     
  • Dow 30

    31,802.44
    +306.14 (+0.97%)
     
  • Nasdaq

    12,609.16
    -310.99 (-2.41%)
     
  • Russell 2000

    2,202.98
    +10.77 (+0.49%)
     
  • Crude Oil

    64.68
    -1.41 (-2.13%)
     
  • Gold

    1,679.80
    -18.70 (-1.10%)
     
  • Silver

    25.18
    -0.11 (-0.42%)
     
  • EUR/USD

    1.1854
    -0.0071 (-0.59%)
     
  • 10-Yr Bond

    1.5960
    +0.0420 (+2.70%)
     
  • GBP/USD

    1.3821
    -0.0007 (-0.05%)
     
  • USD/JPY

    108.8480
    +0.4660 (+0.43%)
     
  • BTC-USD

    51,699.90
    +1,755.52 (+3.51%)
     
  • CMC Crypto 200

    1,047.07
    +22.86 (+2.23%)
     
  • FTSE 100

    6,719.13
    +88.61 (+1.34%)
     
  • Nikkei 225

    28,743.25
    -121.07 (-0.42%)
     

Sage Therapeutics: Q3 Earnings Insights

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Sage Therapeutics (NASDAQ: SAGE) were unchanged after the company reported Q3 results.

Quarterly Results

Earnings per share increased 41.67% year over year to ($2.03), which beat the estimate of ($2.39).

Revenue of $1,639,000 declined by 54.09% year over year, which missed the estimate of $1,860,000.

Looking Ahead

Sage Therapeutics hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

How To Listen To The Conference Call

Date: Nov 05, 2020

View more earnings on SAGE

Time: 08:30 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/7o3nyw69

Price Action

52-week high: $155.33

Company's 52-week low was at $25.01

Price action over last quarter: Up 52.91%

Company Overview

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of the nervous system and brain to discover medicines to treat life-threatening, rare central nervous system disorders. The company's lead development program is SAGE-547, it is in Phase 3 clinical trials for super-refractory status epilepticus; and the SAGE-217 program which is in Phase 2 clinical trials for post-partum depression, essential tremor, Parkinson's disease and major depressive disorder. The company is also developing several other compounds for treatment that is in the early stage of development.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.